Canada markets closed

LEGN Jun 2024 95.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
36.800.00 (0.00%)
At close: 11:08AM EDT
Full screen
Previous Close36.80
Open36.80
Bid33.00
Ask37.50
Strike95.00
Expire Date2024-06-21
Day's Range36.80 - 36.80
Contract RangeN/A
Volume5
Open InterestN/A
  • Business Wire

    Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

    SOMERSET, N.J., June 03, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients. Results showed patients with less than a complete response (CR) after front-line autologous stem cell transplant (ASCT) experienced deep and durable responses following a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with or without lena

  • Business Wire

    Legend Biotech to Participate in the Jefferies Global Healthcare Conference

    SOMERSET, N.J., May 29, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET.

  • Business Wire

    Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

    SOMERSET, N.J., May 23, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new and updated data from the CARTITUDE clinical development program evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Association’s (EHA) Hybrid Congress.